Newron Pharmaceuticals S.p.A.
NP5
Rank in Stocks
#17763
Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in... Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in Bresso, Milano, with a dedicated team of 24 full-time employees. The company's core mission is the discovery and advancement of innovative pharmaceutical products, particularly focusing on new therapies for Central Nervous System (CNS) disorders and pain management. Among its leading candidates, safinamide is currently undergoing Phase III clinical trials for the treatment of Parkinson's disease. Additionally, ralfinamide is being developed as a potential therapy for neuropathic pain. The firm's pipeline further includes a range of projects at various preclinical and clinical development stages, such as HF0220 for neuroprotection, NW-3509 for schizophrenia, and pruvanserin and sarizotan for other CNS conditions.
Share Price
$10.58
Last synced: 2026-10-16
Market Cap
$216.35M
Change (1 day)
1.83%
Change (1 year)
-38.62%
Country
IT
Trade Newron Pharmaceuticals S.p.A. (NP5)
Category
Healthcare
Market Capitalization of Newron Pharmaceuticals S.p.A.(NP5)
Market Cap: $216.35M
As of October 2026 Newron Pharmaceuticals S.p.A. has a market cap of $216.35M. This makes Newron Pharmaceuticals S.p.A. the world's 17763rd most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Market cap history of Newron Pharmaceuticals S.p.A. from 2015 to 2026
NP5 compared with Top 5 Most Popular stocks
